CAS Cord Blood Cells Produce Millions of Cancer-Hunting NK Cells

A single progenitor cell collected from donated umbilical cord blood can now produce millions of laboratory-grown immune cells that seek out cancer.

Making these cells simpler to manufacture at scale could move cancer care towards reliable batches and reduced costs.

Scaling from starter cells

At the Chinese Academy of Sciences (CAS), umbilical cord blood provides progenitor cells that can replicate and develop into consistent batches of immune cells.

Professor Jinyong Wang, Ph.D., and colleagues introduced genetic engineering at an earlier stage, before the cells had matured into cancer killers.

From one progenitor cell, Wang’s team generated 14 to 83 million lab-grown cancer-killing cells, including seven to 32 million versions guided by receptors.

Starting at this early stage may allow clinics to schedule repeated doses without needing to locate fresh donors each time.

What NK cells do

Natural killer cells, commonly known as NK cells, are immune cells that rapidly target abnormal cells within the immune system.

They assess a combination of surface signals to judge whether a cell appears healthy, then create holes that set off the cell’s self-destruction.

In cancer treatment, clinicians can administer donor-derived or laboratory-made NK cells, exposing tumours to a new group of attackers.

Although often appearing safe, many NK therapies remain limited by poor persistence in the body and by cells becoming exhausted over time.

Directing NK cells

Researchers can equip NK cells with a chimeric antigen receptor (CAR), a tailored sensor designed to identify a selected tumour marker.

When the CAR binds its target, it strongly activates the NK cell; this same principle already underpins certain engineered T-cell treatments.

“Chimaeric antigen receptor natural killer (CAR-NK) cells are a promising alternative to CAR-T cells for immunotherapies,” wrote Wang, referring to engineered T cells that are already used against some blood cancers.

Repeated infusions can rapidly deplete available cells, meaning dependable manufacturing is the key bottleneck for CAR-NK therapy.

Editing cells at the source

Rather than modifying fully grown NK cells, the CAS researchers began with early blood-forming stem and progenitor cells obtained from cord blood.

Altering cells at this point meant they replicated the added gene as they divided, leaving more descendant cells with the same modification.

Expanding the cells before NK-cell development also gave engineers an opportunity to remove weak batches before they committed to the NK-cell fate.

This early engineering created a more streamlined process, although the finished cells still needed to develop into killers that function like adult NK cells.

Keeping cells on track

Supportive cell layers supplied growth signals to the expanding progenitor cells, helping them survive as their population rose rapidly.

Following expansion, the researchers placed the cells into organoid aggregates-three-dimensional clusters that reproduce tissue-support signals-to encourage NK development.

These clusters promote activation of genes associated with NK identity while alternative blood-cell developmental routes recede.

Keeping the cells on this route prevented mixed lineages, which could weaken the final dose and make safety assessments more difficult.

Checking cell purity

Correct maturation meant the laboratory-made cells possessed the same weapons used by natural NK cells in the body.

At the end of the process, many cells were able to attack cancer cells marked by antibodies as well as targets they detected directly.

Testing found zero T cells within the mixtures, addressing a frequent concern that unwanted immune cells might cause harm.

Despite producing clean batches, clinicians must still establish how long these NK cells survive after infusion and how frequently doses will be required.

Leukemia tests in mice

In mice carrying human leukaemia, the team directed CAR-NK cells towards a common marker found on B-cell cancers and observed tumour growth slow down.

By binding to that marker on cancer-cell surfaces, the engineered NK cells became activated and destroyed those cells.

The clearest results appeared in B-cell acute lymphoblastic leukaemia (ALL), an aggressive blood cancer involving immature B cells, in which treated animals survived longer.

Human trials will need to verify safety and durability, since mouse studies cannot determine how long CAR-NK cells will persist in patients.

From lab to clinic

Before a therapy can be delivered to patients, laboratories need to freeze, transport and thaw batches without reducing the cells’ cancer-fighting ability.

In testing, frozen CAR-NK cells continued to attack cancer cells after thawing, indicating that clinics could keep doses in stock in advance.

Costs are also reduced when teams require less viral vector-a modified virus used to deliver a new gene-during CAR construction.

More robust batches and less expensive engineering could help CAR-NK products progress towards off-the-shelf use instead of individually tailored treatments.

Limits before human trials

Before any infusion is given, regulators will examine how stable these engineered cells remain and whether storage changes them.

Because viral delivery may place DNA in the wrong location, developers must monitor where the CAR gene integrates into the genome.

Batch scale introduces another practical requirement: manufacturing facilities must show that every run destroys the intended cancer cells while leaving healthy tissue unharmed.

If these safeguards are met, the same approach could be adjusted for other cancer targets rather than only those assessed in this study.

Where this could lead

By first engineering blood-forming progenitor cells, the CAS team demonstrated that one donation can support large-scale production of targeted NK cells.

Clinical trials will determine whether this manufacturing development becomes a routine, affordable therapy or remains a compelling result confined to animals.